SequelSEC

Propanc Biopharma, Inc. PPCB

Pharmaceutical Preparations · CIK 0001517681 · Fiscal year ends 0630

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$3.46M
Fiscal year ended 2026-06-30
Free cash flow
-$1.60M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$47.90KMarket value of stock held by non-affiliates, as stated on the cover page for 2024-12-31
Float per share$0.00Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity0.0×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2024-12-31, not today, and each multiple below it uses the figures for the fiscal year ending 2025-06-30 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio2.55x21th

Propanc Biopharma, Inc. (PPCB) reported net income of -$4.57M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Propanc Biopharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Propanc Biopharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$3.46M-$6.40MUnavailableUnavailable-$3.65M-$53.13MUnavailableUnavailable-$259.90K-$420.87K
Net income-$4.57M-$6.36MUnavailableUnavailable-$4.07M-$54.07MUnavailableUnavailable-$358.58K-$526.70K
Research & development$375.66K$169.66KUnavailableUnavailable$53.52K$54.10KUnavailableUnavailable$52.39K$65.45K
Weighted-average diluted sharesUnavailableshares 22.43MUnavailableUnavailableUnavailableshares 4.33MUnavailableUnavailableUnavailableUnavailable
Pretax income-$4.57M-$6.36MUnavailableUnavailable-$4.07M-$54.07MUnavailableUnavailable-$358.82K-$526.98K
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$237-$275
Diluted EPSUnavailable$-0.28UnavailableUnavailableUnavailable$-12.50UnavailableUnavailableUnavailable$-545.79
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative-$13.78M$6.22MUnavailableUnavailable-$53.33M$53.07MUnavailableUnavailable$192.94K$348.84K
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Propanc Biopharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total assets$12.78M$14.33MUnavailableUnavailable$19.63M$22.53MUnavailableUnavailable$72.36K$37.34K
Current assets$8.54M$8.22MUnavailableUnavailable$8.35M$9.74MUnavailableUnavailable$25.44K$12.86K
Total liabilities$3.38M$3.51MUnavailableUnavailable$5.73M$4.44MUnavailableUnavailable$3.85M$3.74M
Current liabilities$3.35M$3.48MUnavailableUnavailable$5.58M$4.34MUnavailableUnavailable$3.79M$3.69M
Total equity incl. NCI$9.40M$9.83MUnavailableUnavailable$13.91M$18.09MUnavailableUnavailable-$3.78M-$3.70M
Temporary (mezzanine) equityUnavailable$1.00MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailable$55.00KUnavailableUnavailable$537.92K$438.58KUnavailableUnavailable$399.32K$582.95K
Accounts payable$1.13M$973.69KUnavailableUnavailable$1.25M$1.12MUnavailableUnavailable$1.21M$1.19M

Cash flow

Propanc Biopharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$1.60M-$1.14MUnavailableUnavailable-$92.19K-$96.20KUnavailableUnavailable-$259.97K-$102.81K
Capital expenditures$21$154UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$21-$154UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$1.98M$981.61KUnavailableUnavailable$72.76K$147.48KUnavailableUnavailable$250.97K$66.64K
Net change in cash$388.30K-$117.54KUnavailableUnavailable-$38.67K$36.13KUnavailableUnavailable$14.86K-$65.43K
Stock-based compensation$1.23M$1.77MUnavailableUnavailable$3.12MUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Propanc Biopharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$1.60M-$1.14MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio2.55x2.37xUnavailableUnavailable1.50x2.24xUnavailableUnavailable0.01x0.00x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailable0.01xUnavailableUnavailable0.04xUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PPCB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-K · Filed 2026-09-25View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-Q · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-K · Filed 2025-09-29View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

16 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2025-12-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-12-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-09-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-09-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-12-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-12-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-09-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-09-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-12-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-12-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-09-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-09-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.